

University of Montana

ScholarWorks at University of Montana

University of Montana Course Syllabi

Open Educational Resources (OER)

Fall 9-1-2001

PHAR 553.01: Therapeutics III

Michael P. Rivey

University of Montana, Missoula

Follow this and additional works at: <https://scholarworks.umt.edu/syllabi>

Let us know how access to this document benefits you.

Recommended Citation

Rivey, Michael P., "PHAR 553.01: Therapeutics III" (2001). *University of Montana Course Syllabi*. 6206.
<https://scholarworks.umt.edu/syllabi/6206>

This Syllabus is brought to you for free and open access by the Open Educational Resources (OER) at ScholarWorks at University of Montana. It has been accepted for inclusion in University of Montana Course Syllabi by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact scholarworks@mso.umt.edu.

Pharmacy 553 Pharm.D.: Therapeutics III Fall 2001

Lectures: M-W-F 1110-1200 Skaggs Bldg Rm 117
F only 1010-1100 " Rm 114

Course Coordinator: Michael Rivey =====> M. Rivey
Instructors: Douglas Allington Office: 243-6796
Rose Macklin Community Hosp: 327-4299
Cathy Bartels ext. 7605
Sarah Miller Pager: 329-6122
Gayle Cochran Home: 251-3369
Donna Beall
Lee Ann Bradley

Material and Resources

Required Texts: DiPiro *Pharmacotherapy, 4th edition*
APhA: *Handbook of Nonprescription Drugs*
Medical Letter on Drugs & Therapeutics
Goodman & Gilman's *Pharmacological Basis of Therapeutics*
Boh *Pharmacy Practice Manual*
A medical dictionary

Optional Texts: Murphy: *Clinical Pharmacokinetics pocket reference*
Evans: *Applied Pharmacokinetics*
Young, Koda-Kimble: *Applied Therapeutics*
Herfindal, Gourley, Hart: *Clinical Pharmacy and Therapeutics*
Hansten & Horn: *Drug Interactions*
Pagana & Pagana: *Diagnostic & Lab Test Ref.*, or other lab. text

Goals of the Course

To promote the students' understanding of common disease states with particular emphasis on the facets of diseases that are amenable to drug therapy.

To familiarize the student with the proper use of drugs in a clinical setting.

To develop the students' awareness of factors that should be considered prior to selection of a drug and the appropriate parameters that should be monitored for therapeutic as well as undesired effects.

To encourage the students' ability to problem-solve in the clinical setting.

Performance Objectives

Upon completion of this course, each student shall be able to:

Relate the pathophysiology of a disease to the known or purported action of a drug.

Evaluate the seriousness of a disorder based on the signs and symptoms related to a diagnosed problem, and:

- determine the necessity of drug therapy,
- when applicable, choose the proper drug and/or drug product for the situation.

Determine the place of non-pharmacologic and natural therapies, when applicable.

Tailor the drug therapy of an individual based on patient characteristics and known pharmacokinetics principles.

Identify potential drug-drug interactions.

Monitor the appropriate parameters of a disease to determine if the patient is responding positively to therapy.

Monitor for adverse drug reactions and exacerbations of underlying patient problems resulting from drug therapy.

Student Responsibilities and Obligations

- * To attend and participate in lecture sessions.
- * To do assigned readings from the texts.
- * To attend Integrated Studies conferences, prepare each case in advance, to present a patient case, and participate in the discussion of all patient presentations.
- * To perform satisfactorily on course quizzes and lecture examinations.

GRADING IN COURSE: Phar 553 Therapeutics III

3 midterm exams: 100 points each	300 points
Final exam (comprehensive, multiple choice) (100 pts comprehensive, 30 pts over last 6 lectures)	130 points
Topic quizzes: 8 quizzes graded on 10 pts each	<u>Bonus pts > 75%</u>
TOTAL POINTS FOR COURSE	430 POINTS

Class quizzes: The purposes of the quizzes are to promote reading of the text before a topic and encourage class attendance and attention. Quizzes will occur before topic lectures and will test understanding of basic concepts in the reading assignment, and will cover only chapter/reading material associated with the day the quiz is scheduled. A quiz will consist of 5 multiple choice or true/false questions, each worth 2 points. **QUIZ** on syllabus indicates a quiz will be given for assigned reading at start of the given lecture. Lowest 2 quiz grades will be thrown out; **no make-ups will be allowed** for quiz. **Scoring: Quiz performance can only benefit student;** bonus points for the course will be awarded for all points over 75% (i.e. 60 pts) of the potential total 80 pts on the quizzes (10 total quizzes – 2 throw-outs = 8x10 pts)

NOTE: Reading assignments are from DiPiro (4th edition) & APhA books

Integrated Studies Conferences: you will be assigned to a conference based on period you registered for; instructors are not necessarily the ones under which you registered. Attendance/make-up **is required** for all topics/cases; you may attend a different conference in order to complete the assignment, but **ONLY** with instructor permission. The “make-up” requirement for a conference missed due to unavoidable incident will be at the discretion of the instructor, dependent on the topic. Failure to complete any conference will result in a grade of “fail” for course.

Exams:

3 midterm exams: Tests will be in "traditional" case report fashion with short answers required. Tests will be given during a “common” time period. B.S. and Pharm.D. classes will take tests simultaneously.

Final exam: 65 multiple choice questions worth 2 pts each. Effort will be made to design questions in the style similar to the NAPLEX exam.

Class civility: Your **student colleagues** have strongly indicated to us that they wish to spend their valuable time in class listening to therapeutics topics. They **do not** appreciate any “side” conversations while the instructor is lecturing. They **do** appreciate students raising questions about important lecture aspects for further discussion or clarification.

Out of respect for your classmates, we will not tolerate excessive and disruptive talking during lecture. The instructor may first ask you to be silent; you may be asked to leave class if you persist in disruptive talking. The instructor will be the judge of “what” constitutes disruption. Please note that we **encourage** questions and relevant discussion.

Therapeutics 553 Pharm.D.: Lecture Syllabus

* denotes "early" 1010-1100 Friday lecture; "joint" denotes **B.S. class will join**

			Instructor	Reading
Sept	5W	Introduction/ Liver disease	MPR	
	7F*	Renal disease/ joint/ QUIZ	DRA	40
	7F	Liver disease	MPR	38
	10M	Liver Disease	MPR	35
	12W	Renal disease	DRA	41
	14F*	Pain Management/ joint	LAB	56
	14F	Renal disease	DRA	42
	17M	Pain mgmt/ joint	LAB	
	19W	Headache/ joint/ QUIZ	DB	57
	21F*	Headache/ joint	DB	OTC 3
	21F	Nausea & vomiting	LAB	33, OTC 5
	24M	N&V, emetics	LAB	OTC 25
	25T	Career Fair		
	26W	Oncology	CLB	DiPiro pp. 1957-71
	28F*	Oncology	CLB	pp. 2002-7
28F	Oncology	CLB	pp. 2013-41	
Oct	1M	Oncology	CLB	pp. 2046-57
	3W	Arthritis / joint/ QUIZ	MPR	84
	5F*	Arthritis	MPR	83
	5F	Arthritis/ joint	MPR	OTC pp71-74,OTC 5
	5F	Test 1 at 1-3 PM in SB ; through Oncology		
	8M	Gout/ joint	MPR	85
	10W	Systemic Lupus Erythematosus	LRM	80
	12F*	Contraception/ joint/ QUIZ	DB	OTC 8
	12F	Contraception	DB	76
	15M	Contraception	DB	
	17W	Urinary disorders	DRA	OTC 44
	19F*	off, in lieu of test 1		
	19F	off, in lieu of test 2 ASP-MRM in Seattle		
	22M	Menopause/ joint/ QUIZ	GAC	78
	24W	Menopause/ joint	GAC	
26F*	Osteoporosis/ joint	GAC	82, OTC 419-20	
26F	off, in lieu of test 3			

553-Ther III, continued

Oct	29M	Osteoporosis/ joint	GAC	
	31W	Obstruct. Airways Dx/ joint/ QUIZ	DRA	24
Nov	2F*	OAD/ joint	DRA	25, OTC 10
	2F	Theophylline kinetics	DRA	
	2F	Test 2 at 1-3PM in SB114; through osteoporosis		
	5M	Theophylline PK/respiratory equip	DRA	
	7W	Thromboembolic disease/ joint	MPR	17
	9F*	Stroke/ joint/ QUIZ	MPR	18
	9F	TED	MPR	
	12M	Veterans Day		
	14W	Peripheral Vascular Disease	MPR	20
	16F*	Fluid & electrolytes/ QUIZ	SJM	DiPiro pp. 890-902
	16F	F & E	SJM	pp. 902-16
	19M	F & E	SJM	
	21W	OFF; TRAVEL DAY		
	22Th	THANKSGIVING HOLIDAY		
	23F	“ “		
	26M	Nutrition support	SJM	128
	28W	Nutrition support	SJM	129
	30F*	Nutrition support	SJM	
	30F	Nutrition support	SJM	
Dec	3M	Diabetes mellitus/ QUIZ	LRM	70
	5W	DM	LRM	
	7F*	DM	LRM	
	7F	DM	LRM	
	7F	test 3 at 1-3 PM in SB 114; through nutrition support		
	10M	DM diet/tests	LRM	OTC 39
	12W	CLASS EVAL/ Thyroid dx/ QUIZ	MPR	71
	14F*	Thyroid disorders/	MPR	
	14F	Thyroid dx	MPR	

Final: test 4, 130 pts comprehensive multiple choice NAPLEX/PSAP format

Merged classes: for certain classes, B.S. students will merge with the P.D. students, denoted as “**joint**”- this does not affect P.D. time or location of class.

Integrated Studies Phar 571

Monday 0910-1100	SB 111	Macklin
Monday 0910-1100	SB 215	Allington
Wednesday 0910-1100	SB 215	Rivey
Wednesday 0910-1100	SB 335	Allington
Wednesday 0910-1100	SB 337	Macklin

I. Conference topics

week of:

September	3M	No conference
	10M	Liver disease case
	17M	Renal Disease case
	24M	Headache/pain management
October	1M	J-club for ½ of class; service learning project worksession
	8M	Arthritis case
	15M	OTC cases
	22M	Contraception
	29M	service learning update: J-club for other ½ of class
November	5M	SEMINARS
	12M	OAD case
	19M	off week- holiday week
	26M	TED case
December	3M	OTC cases
	11M	Evaluation/Diabetes case

Seminar: A required activity in the course, graded on a pass/no-pass basis. Student must repeat a no-pass seminar to successfully pass course.